Loading…
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.1B | $284M | $95M | $182M | -14.6% | -3.8% | 21.8% |
| 2024 | $1.1B | $193M | $78M | $20M | -10.6% | 0.2% | 11.2% |
| 2023 | $1.1B | $245M | $70M | $41M | -8.6% | -0.8% | -68.5% |
| 2022 | $1.1B | $335M | $224M | $388M | -25.1% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,129.50 | 1,120.80 | 1,123.10 | 1,080.40 |
| Cost Of Revenue | - | 354.60 | 370.90 | 387.90 | 403.60 |
| Gross Profit | - | 774.90 | 749.90 | 735.20 | 676.80 |
| Operating Expense | - | 406.40 | 525.90 | 450.20 | 380.40 |
| Operating Income | - | 368.50 | 224 | 285 | 296.40 |
| EBITDA | - | 334.50 | 245.30 | 192.70 | 284.30 |
| EBIT | - | 302.80 | 212.70 | 156.50 | 243.60 |
| Pretax Income | - | 256.60 | 105.70 | 44.20 | 136.30 |
| Tax Provision | - | 33 | 35.30 | -34.10 | 40.90 |
| Net Income | - | 223.60 | 70.40 | 78.30 | 95.40 |
| Net Income Common Stockholders | - | 223.60 | 70.40 | 78.30 | 95.40 |
| Total Expenses | - | 761 | 896.80 | 838.10 | 784 |
| Interest Expense | - | 46.20 | 107 | 112.30 | 107.30 |
| Research And Development | - | 66.90 | 85.20 | 78.80 | 37.30 |
| Selling General And Administration | - | 294.80 | 341.30 | 365.10 | 332 |
| Normalized EBITDA | - | 393.40 | 247.80 | 310.90 | 338.60 |
| Normalized Income | - | 274.90 | 72.06 | 171.68 | 133.41 |
| Market Cap | 546.01 | 546.01 | 546.01 | 546.01 | 546.01 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Embecta Corp.this co. | EMBC | $536M | 5.72↓ discount | -0.84 | -14.6% | 6.16 |
| NeuroPace, Inc. | NPCE | $562M | - | 29.17 | -112.8% | -35.19 |
| Rigel Pharmaceuticals, Inc. | RIGL | $540M | 1.50 | 1.37 | 93.8% | 3.43 |
| SI-BONE, Inc. | SIBN | $528M | - | 2.93 | -10.6% | -25.11 |
| Personalis, Inc. | PSNL | $528M | - | 1.98 |
| - |
| - |
| - |
| - |
| -31.1% |
| -4.25 |
| Tactile Systems Technology, Inc. | TCMD | $512M | 27.44 | 2.31 | 8.7% | 12.18 |
| Altimmune, Inc. | ALT | $511M | - | 1.30 | -39.2% | -1.10 |
| Tectonic Therapeutic, Inc. | TECX | $510M | - | 2.02 | -29.5% | -3.09 |
| Aquestive Therapeutics, Inc. | AQST | $503M | - | -14.67 | 248.9% | -5.90 |
| Peer Median | - | 14.47 | 2.00 | -20.1% | -3.67 | |